Cardiac arrest & resuscitation
Neurofilament light chain evaluated with a new automated commercially available method for outcome prediction in out-of-hospital cardiac arrest patients
Primary result · AUROC for poor outcome (CPC 3-5)Result — go to the resultDifference in AUROC −0.008-0.001Authors' conclusion
The Atellica NfL assay accuracy appears well comparable to that obtained using the more laborious Simoa method.
Study context
- Population
- Out-of-hospital cardiac arrest (OHCA) patients in the COMACARE trial, samples collected 2016–2017
- Participants
- 112 patients
- Comparison
- Siemens Atellica Neurofilament Light (NfL) vs Quanterix Simoa NF-Light
- Primary endpoint
- Prognostic accuracy (AUROC) of plasma NfL measured at 24–72 h for poor outcome (Cerebral Performance Category (CPC) 3-5)
- Follow-up
- Six months after OHCA
Methodological detailsdiagnostic/prognostic accuracy, method comparison
- Diagnostic/prognostic accuracy
- Method comparison
Primary result
AUROC for poor outcome (CPC 3-5)
Difference in AUROC
−0.008-0.001
By group
Atellica NfL
0.97-0.98
AUROC
As reported in the abstract
Further findings
Atellica NfL cut-offs for poor outcome with 99 % specificity (tentative, limited sample size) · six months after OHCA
ng/L
- Cut-off at 24 h
- 112
- Cut-off at 48 h
- 229
- Cut-off at 72 h
- 331
Atellica NfL cut-offs for good outcome with 100 % sensitivity
- Cut-off at 24, 48 and 72 h
- below 29 ng/L
Original publication
Neurofilament light chain evaluated with a new automated commercially available method for outcome prediction in out-of-hospital cardiac arrest patients. Resuscitation. Published 27 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →